1
Clinical Trials associated with QLF-31911QLF31911 注射液在晚期恶性肿瘤患者中的安全性、耐受性以及药代动力学的 I 期临床研究
[Translation] Phase I clinical study on the safety, tolerability and pharmacokinetics of QLF31911 injection in patients with advanced malignant tumors
单药剂量递增主要研究目的:评价 QLF31911 单药在晚期恶性肿瘤患者中的安全性和耐受性,确定RP2D 。
次要研究目的:观察 QLF31911 在晚期恶性肿瘤患者中静脉给药后的 PK特征;评价 QLF31911 在晚期恶性肿瘤患者中的免疫原性;评价 QLF31911 在晚期恶性肿瘤患者中的初步疗效。
[Translation] Single-drug dose escalation The main study objectives are: to evaluate the safety and tolerability of QLF31911 monotherapy in patients with advanced malignant tumors and determine the RP2D.
Secondary study objectives: to observe the PK characteristics of QLF31911 after intravenous administration in patients with advanced malignant tumors; to evaluate the immunogenicity of QLF31911 in patients with advanced malignant tumors; to evaluate the preliminary efficacy of QLF31911 in patients with advanced malignant tumors.
100 Clinical Results associated with QLF-31911
100 Translational Medicine associated with QLF-31911
100 Patents (Medical) associated with QLF-31911
100 Deals associated with QLF-31911